ConductScience.org, home

Paper273269

Radiosensitization by misonidazole (Ro 07-0582). The importance of timing and tumor concentration of sensitizer.

McNally NJ and 4 others. Radiat Res, 1978. Cited by 64 papers, by iCite.

Cite this record

ConductScience Library. Radiosensitization by misonidazole (Ro 07-0582). The importance of timing and tumor concentration of sensitizer. Papers, record 273269. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/273269

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Radiosensitization by misonidazole (Ro 07-0582). The importance of timing and tumor concentration of sensitizer.
PubMed
Journal
Radiat Res
PubMed
Year
1978
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
64
iCite
Relative citation ratio, by iCite
4.78
iCite
Revised in PubMed
2013-11-21
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1McNally NJN J
2Denekamp JJ
3Sheldon PP
4Flockhart IRI R
5Stewart FAF A

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Neoplasms, ExperimentalMajor topic
NitroimidazolesMajor topic
Radiation-Sensitizing AgentsMajor topic
Animals
Female
Fibrosarcoma
Male
Mammary Neoplasms, Experimental
Mice
Neoplasm Transplantation
Osteosarcoma
Oxygen
Time Factors
Transplantation, Isogeneic

Source PubMed

Download CSV of topics

Cited by18

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 64 citations.

PMIDTitleJournalYearIn PapersSource
7460192Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice.Cancer Chemother Pharmacol1980https://conductscience.org/library/papers/7460192PubMed
7427595Radiosensitisers.Br Med J1980https://conductscience.org/library/papers/7427595PubMed
7370170Phenytoin shortens the half-life of the hypoxic cell radiosensitizer misonidazole in man: implications for possible reduced toxicity.Br J Cancer1980https://conductscience.org/library/papers/7370170PubMed
7362770Effect of misonidazole and hyperthermia on the radiosensitivity of a C3H mouse mammary carcinoma and its surrounding normal tissue.Br J Cancer1980https://conductscience.org/library/papers/7362770PubMed
7362769Is tumour radiosensitization by misonidazole a general phenomenon?Br J Cancer1980https://conductscience.org/library/papers/7362769PubMed
7295516Phenytoin-induced changes in the pharmacokinetics of misonidazole in radiotherapy patients.Br J Cancer1981https://conductscience.org/library/papers/7295516PubMed
7248157Enhancement of the effect of cytotoxic drugs by radiosensitizers.Br J Cancer1981https://conductscience.org/library/papers/7248157PubMed
7104192In vivo assessment of basic 2-nitroimidazole radiosensitizers.Br J Cancer1982https://conductscience.org/library/papers/7104192PubMed
7059476The penetration of misonidazole into a mature structural cartilage.Br J Cancer1982https://conductscience.org/library/papers/7059476PubMed
6932914In vivo-in vitro tumour cell lines: characteristics and limitations as models for human cancer.Br J Cancer Suppl1980https://conductscience.org/library/papers/6932914PubMed
6547051Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo.Br J Cancer1984https://conductscience.org/library/papers/6547051PubMed
6519157The pharmacokinetics of a new radiosensitiser, Ro 03-8799 in humans.Eur J Clin Pharmacol1984https://conductscience.org/library/papers/6519157PubMed
3719893Distribution and tumor penetration properties of a radiosensitizer 2-[14C] misonidazole (Ro 07-0582), in mice and rats as studied by whole-body autoradiography.Cancer Chemother Pharmacol1986https://conductscience.org/library/papers/3719893PubMed
2110814Bioreductive drugs and the selective induction of tumour hypoxia.Br J Cancer1990https://conductscience.org/library/papers/2110814PubMed
508562Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in mice.Br J Cancer1979https://conductscience.org/library/papers/508562PubMed
486305Distribution of misonidazole in human tumours and normal tissues.Br J Cancer1979https://conductscience.org/library/papers/486305PubMed
465300Pharmacokinetic considerations in testing hypoxic cell radiosensitizers in mouse tumours.Br J Cancer1979https://conductscience.org/library/papers/465300PubMed
289406The penetration of misonidazole into spontaneous canine tumours.Br J Cancer1979https://conductscience.org/library/papers/289406PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/273269

GET https://conductscience.org/api/papers/v1/273269/authors